The CEO of Seattle Genetics, Dr. Clay Siegall, has a blog filled with content that he wants to share with others. Lately he has been sharing a lot of NFL news. One of the articles is about the return of Corey Davis of the Tennessee Titans after an injury to his hamstring. He was able to recover from the injury and is now practicing with the rest of the team.
In other NFL news Dr. Siegall shares that the New Orlean Saints have now received their defensive linebacker Jason Jones from the team. He had signed with the Saints earlier this month and had been cut by the Dolphins earlier in the year. He has been in the league for nine years. The Saints also announced that they placed their Tight End John Phillips on the injured reserve list.
It was in 1998 that Dr. Clay Siegall established Seattle Genetics. His company creates targeted cancer drug therapies. They have one drug already on the market that treats which treats Hodgkin lymphoma as well as another form of lymphoma called Adcetris. His company specializes in ADC technology which stands for antibody-drug conjugates.
Dr. Clay Siegall has developed a number of strategic licensing agreements with other pharmaceutical companies. Among these other corporations are Pfizer, AbbVie, and GlaxoSmithKline. Including the drugs they are either internally or co-developing with other pharmaceutical companies they have more than 20 cancer drugs under various stages of development.
In addition to his leadership at Seattle Genetics Dr. Siegall also serves as a board director for other biopharmaceutical companies. He serves in this capacity for Alder Biopharmaceuticals, Inc. and Mirna Therapeutics, Inc. He also serves in the role for Ultragenyx Pharmaceutical, a company he has been involved with since 2014. During his career he has won a number of awards including Entrepreneur of the Year. He was also named Alumnus of the Year for Computer, Math, and Natural Sciences by his alma mater George Washington University. At this university he earned his doctor of philosophy in genetics.